These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31109249)

  • 21. Public health genomics and personalized prevention: lessons from the COGS project.
    Pashayan N; Hall A; Chowdhury S; Dent T; Pharoah PD; Burton H
    J Intern Med; 2013 Nov; 274(5):451-6. PubMed ID: 24127941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical implementation of pharmacogenetics.
    García-González X; Cabaleiro T; Herrero MJ; McLeod H; López-Fernández LA
    Drug Metab Pers Ther; 2016 Mar; 31(1):9-16. PubMed ID: 26751902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Norwegian Cancer Genomics Consortium: a platform for research on personalized cancer medicine in a public health system.
    Myklebost O
    Drug Discov Today; 2015 Dec; 20(12):1419-21. PubMed ID: 26520668
    [No Abstract]   [Full Text] [Related]  

  • 24. A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice.
    Arnall JR; Petro R; Patel JN; Kennedy L
    J Oncol Pharm Pract; 2019 Jan; 25(1):179-186. PubMed ID: 29078708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does personalized medicine exist and can you test it in a clinical trial?
    Sandercock PA
    Int J Stroke; 2015 Oct; 10(7):994-9. PubMed ID: 26282857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isogenic mutant human cells: a new tool for personalized cancer medicine.
    Di Nicolantonio F; Arena S; Gallicchio M; Bardelli A
    Cell Cycle; 2010 Jan; 9(1):20-1. PubMed ID: 20016269
    [No Abstract]   [Full Text] [Related]  

  • 27. Functional genomics for personalized cancer therapy.
    Tyner JW
    Sci Transl Med; 2014 Jul; 6(243):243fs26. PubMed ID: 24990879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
    Murciano-Goroff YR; McCarthy AM; Bristol MN; Groeneveld P; Domchek SM; Motanya UN; Armstrong K
    Breast Cancer Res Treat; 2018 Aug; 171(1):173-180. PubMed ID: 29737473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenomics and personalized medicine in clinical practice.
    Manolopoulos VG; Dechairo B; Huriez A; Kühn A; Llerena A; van Schaik RH; Yeo KT; Ragia G; Siest G
    Pharmacogenomics; 2011 May; 12(5):597-610. PubMed ID: 21619425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New "Fast-Second Winner" Strategy.
    Mitropoulos K; Cooper DN; Mitropoulou C; Agathos S; Reichardt JKV; Al-Maskari F; Chantratita W; Wonkam A; Dandara C; Katsila T; Lopez-Correa C; Ali BR; Patrinos GP
    OMICS; 2017 Nov; 21(11):647-657. PubMed ID: 29140767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer genomics guide clinical practice in personalized medicine.
    Lehmann-Che J; Poirot B; Boyer JC; Evrard A
    Therapie; 2017 Sep; 72(4):439-451. PubMed ID: 28258721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice.
    LLerena A; Peñas-Lledó EM
    Drug Metab Pers Ther; 2015 Sep; 30(3):143-5. PubMed ID: 26353178
    [No Abstract]   [Full Text] [Related]  

  • 33. The Daniel K. Inouye College of Pharmacy Scripts: Precision Medicine Through the Use of Pharmacogenomics: Current Status and Barriers to Implementation.
    Ciarleglio AE; Ma C
    Hawaii J Med Public Health; 2017 Sep; 76(9):265-269. PubMed ID: 28900583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementing Precision Medicine Programs and Clinical Trials in the Community-Based Oncology Practice: Barriers and Best Practices.
    Ersek JL; Black LJ; Thompson MA; Kim ES
    Am Soc Clin Oncol Educ Book; 2018 May; 38():188-196. PubMed ID: 30231363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Personalized medicine, genomics, and pharmacogenomics: a primer for nurses.
    Blix A
    Clin J Oncol Nurs; 2014 Aug; 18(4):437-41. PubMed ID: 25095297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From systems biology and functional genomics to personalized health. 5th Biologie Prospective Santorini Conference, Island of Santorini, Greece, September 30-October 2, 2010.
    Drug Metabol Drug Interact; 2011; 26(1):41-2. PubMed ID: 21417796
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.
    Bank PCD; Caudle KE; Swen JJ; Gammal RS; Whirl-Carrillo M; Klein TE; Relling MV; Guchelaar HJ
    Clin Pharmacol Ther; 2018 Apr; 103(4):599-618. PubMed ID: 28994452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementing Precision Medicine: The Ethical Challenges.
    Korngiebel DM; Thummel KE; Burke W
    Trends Pharmacol Sci; 2017 Jan; 38(1):8-14. PubMed ID: 27939182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics and Personalized Medicine in Pancreatic Cancer.
    Hosseini Bereshneh A; Morshedi F; Hematyar M; Kaki A; Garshasbi M
    Acta Med Iran; 2017 Mar; 55(3):194-199. PubMed ID: 28282719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review).
    Vizirianakis IS; Mystridis GA; Avgoustakis K; Fatouros DG; Spanakis M
    Oncol Rep; 2016 Apr; 35(4):1891-904. PubMed ID: 26781205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.